Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $67.00 at The Goldman Sachs Group

Enliven Therapeutics (NASDAQ:ELVN) had its price target hoisted by The Goldman Sachs Group from $59.00 to $67.00 in a research report released on Tuesday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock.

Other analysts also recently issued research reports about the company. HC Wainwright lifted their target price on Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Guggenheim initiated coverage on Enliven Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $80.00 price target on the stock. Finally, Stifel Nicolaus upped their price objective on Enliven Therapeutics from $60.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $70.50.

Enliven Therapeutics Trading Up 5.1%

Shares of ELVN opened at $54.33 on Tuesday. The stock has a market capitalization of $3.31 billion, a price-to-earnings ratio of -32.53 and a beta of 0.24. Enliven Therapeutics has a 12 month low of $14.78 and a 12 month high of $54.88. The firm has a fifty day simple moving average of $44.88 and a 200 day simple moving average of $36.64.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.06. As a group, research analysts predict that Enliven Therapeutics will post -1.57 earnings per share for the current fiscal year.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, Director Lori Anne Kunkel sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $50.49, for a total transaction of $504,900.00. Following the transaction, the director owned 41,884 shares of the company’s stock, valued at $2,114,723.16. The trade was a 19.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $43.80, for a total value of $263,588.40. Following the transaction, the chief financial officer directly owned 51,000 shares in the company, valued at approximately $2,233,800. This trade represents a 10.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 26,018 shares of company stock worth $1,113,888. 3.00% of the stock is owned by insiders.

Institutional Trading of Enliven Therapeutics

A number of hedge funds have recently made changes to their positions in the business. KBC Group NV acquired a new position in shares of Enliven Therapeutics during the 1st quarter worth approximately $38,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Enliven Therapeutics by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in Enliven Therapeutics during the fourth quarter worth $83,000. Finally, Quantbot Technologies LP boosted its position in Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.